

CURRICULUM VITAE

DR LAURENCE KENNEDY

Birth place - Belfast, Northern Ireland, January 24, 1948

Work address - Division of Endocrinology, Department of Medicine,
University of Florida, 1600 SW Archer Road,
Gainesville, Florida, 32610.
Tel (352) 846 2230 Fax (352) 846 2231
e-mail - kenneal@medicine.ufl.edu

**Current Position - Associate Professor and Chief,
Division of Endocrinology,
Department of Medicine,
University of Florida, Gainesville, Fl 32610-0226.**

Married - Wife, Sarah Louise, 2 sons - Christopher, b 1981, Jonathan, b 1985

Florida Medical License: MFC 0001272

Education:

Medical Undergraduate 1966-1972
1972 MB, BCh, BaO, Queen's University Belfast, Northern Ireland.
1975 MRCP (UK)
1978 ECFMG & VQE
1979 Federal Licensure Examination (FLEX)
1982 MD by thesis, Queen's University, Belfast
1988 FRCP Edinburgh
1990 FRCP London

Professional Experience

1972-73 Junior House Officer (Intern), Royal Victoria Hospital, Belfast, Northern Ireland

- 1973-76 General Medical Training (Residency), Belfast Teaching Hospitals
 1976-78 Senior Registrar in Endocrinology and Diabetes, Royal Victoria Hospital, Belfast
- 1978-80 Research Fellow and Clinical Instructor in Endocrinology, Department of Medicine,
 University of Florida, Gainesville, Florida
- 1980-92 Consultant Physician (Endo/Diabetes/Medicine), Royal Victoria Hospital, Belfast
 1992-94 Consultant Physician (General Medicine, Diabetes), Ards Hospital, N Ireland
 1994-96 Consultant Physician (Diabetes/Endo/Medicine), Dr Gray's Hospital, Elgin, Scotland
- 1996-97 Clinical Associate Professor of Medicine,
 Division of Endocrinology, Department of Medicine,
 University of North Carolina, Chapel Hill
- 1997 to present Associate Professor and Director of Clinical Services,
 Endocrine Division, Dept of Medicine;
 University of Florida, Gainesville, Florida.
- 1999 to 2001 Interim Chief, Division of Endocrinology & Metabolism
 Department of Medicine, University of Florida
 Gainesville, Florida
- 2001 to present Chief, Division of Endocrinology & Metabolism
 Department of Medicine, University of Florida
 Gainesville, Florida

Awards and Distinctions:

- 1967 1st Medical Scholarship, Queen's University, Belfast
 1978 Samuel Haslett Browne Travelling Scholarship, Queen's University, Belfast
 1985 Nordisk Irish Endocrine Society Lecturer (Inaugural year)

Membership and involvement in Learned Societies

British Diabetic Association -

- Member, Medical and Scientific Section, 1977 to present
- Committee member, Medical and Scientific Section, 1984-87
- Research Committee member, 1986-89
- Chairman, Northern Ireland Committee, 1988-93
- Executive Council Member, 1988-93

- Irish Endocrine Society - member 1976 to present
 - Committee, 1984-87

European Association for the Study of Diabetes - member 1977 to present

Endocrine Society (USA) - member 1980 to present

Society for Endocrinology (UK) - member 1981 to present

Association of Physicians of GB & Ire - elected to membership 1988

American Diabetes Association - member 1997 to present

Teaching Experience - Since 1976 I have been involved in undergraduate and post graduate teaching of medicine to medical students and doctors every year in every institution in which I have worked, and at various times have taught nurses, pharmacy students, laboratory technical staff and students. Specific lecture courses I have been involved in include, but are not limited to, the following:-

Diabetes and endocrine undergraduate lecture course, University of Florida, Gainesville, FL, 1978-80

Clinical Lecture Course for diabetes and endocrinology, Queen's University, Belfast, 1980-1993 (Course Coordinator 1990-93)

Advanced training Courses in Diabetes sponsored by the British Diabetic Association 1985, 1988

Editing and Reviewing

1985-1988 Associate Editor of Diabetologia

Reviewer for the following journals: Diabetologia, Diabetes, Diabetes Care, Diabetic Medicine,

Journal of Clinical Investigation, Acta Endocrinologica, Diabetes Nutrition & Metabolism, Clinical Research, American Journal of Pathology, Ulster Medical Journal, Annals of Internal Medicine, Metabolism.

Reviewer of grant applications to the British Diabetic Association and to the Wellcome Medical Trust

Other Educational Activities

1987-92 Member of Standing Advisory Committee on General Medicine, Northern Ireland
1988-92 Member of Standing Advisory Committee of the Royal College of Physicians of London on Diabetes and Endocrinology
1998 to present Director of Endocrine Fellowship Program, University of Florida.

Research Interests

Clinical trials in diabetes

Glycation of proteins, hemoglobin

Microvascular and macrovascular complications and glycemic control

Effects of diet on lipids, insulin secretion in diabetes

Diagnosis and treatment of Cushing's syndrome

Clinical research in general endocrinology

PUBLICATIONS

Diabetes Research and Clinical Studies

- 1) **Kennedy L**, Lappin TRJ, Lavery TD et al. Relation of high density lipoprotein cholesterol to type of diabetes and its control. *British Med J* 1978, 2, 1191-94.
- 2) **Kennedy L**, Kandell TD, Merimee TJ. Serum protein bound hexose in diabetes. *Diabetes* 1979, 28, 1006-09.
- 3) **Kennedy L**, Mehl TD, Merimee TJ. Non-enzymatically glycosylated serum protein: spurious elevation due to free glucose in serum. *Diabetes* 1980, 29, 413-15.
- 4) **Kennedy L**, Merimee TJ. Glycosylated hemoglobin and diabetic control. *Annals Int Med* 1980 (letter)
- 5) **Kennedy L**, McComb JE, Campbell SL. HbA1c, home urine sugar testing and HDL and total cholesterol in diabetic children. *Irish J Med Sci* 1980, 149, 295-98.
- 6) Elder E, **Kennedy L**, Daly JG et al. Antithrombin III and other coagulation factor changes in proliferative diabetic retinopathy. *Haemostasis* 1980, 29, 413-16.
- 7) **Kennedy L**, Merimee TJ. Glycosylated serum protein and hemoglobin A1c levels to measure control of glycemia. *Annals Int Med* 1981, 95, 56-57.
- 8) **Kennedy L**, Mehl TD, Riley W, Merimee TJ. Non-enzymatically glycosylated serum protein in diabetes - an index of short-term glycaemia. *Diabetologia*, 1981, 21, 94-98.
- 9) Merimee TJ, **Kennedy L**, Mehl T, Rosenbloom A. Serum glucosidase activity in diabetes mellitus. *Diabetes*, 1981, 30, 115-17.

- 10) **Kennedy L**, Elder E, Mehl T et al. Non-enzymatic glycosylation of serum and plasma proteins. *Diabetes* 1982, 31 (Suppl 2), 52-56.
- 11) **Kennedy L**, Beacom R, Archer D et al. Limited joint mobility in Type1 diabetes mellitus. *Postgrad Med J* 1982, 58, 481-84.
- 12) Johnston PB, Kidd M, **Kennedy L**, et al. Analysis of HLA antigen association with proliferative diabetic retinopathy. *British J Ophthalmol* 1982, 66,277-79.
- 13) **Kennedy L**, Walshe K, Hadden DR et al. Effect of dietary therapy on serum HDL cholesterol in patients with type 2 (non-insulin-dependent) diabetes - a prospective study. *Diabetologia* 1982, 23, 24-28.
- 14) Elder E, **Kennedy L**. Improved rapid assay of glycosylated serum proteins. *Diabetologia* 1983, 24, 70-71.
- 15) Varghese M, Walshe K, Bell PM, Hadden DR, **Kennedy L**, Weaver JA. Continuous subcutaneous insulin infusion in insulin-dependent diabetes. *Irish J Med Sci* 1983, 152, 94-98.
- 16) Lyons TJ, **Kennedy L**, Atkinson AB et al. Predicting the need for insulin therapy in late onset (40-69 years) diabetes mellitus. *Diabetic Med* 1984, 1, 105-08.
- 17) Byrne E, Savage G, Merrett D, **Kennedy L**. Routine measurement of HbA1c at the diabetic outpatient clinic. *Ulster Med J* 1984, 53, 51-57.
- 18) Lyons TJ, **Kennedy L**. Non-enzymatic glycosylation of skin collagen in patients with Type 1 (insulin-dependent) diabetes mellitus and limited joint mobility. *Diabetologia* 1985, 28, 2-5.
- 19) Beacom R, Gillespie E, Middleton D, SawhneyB, **Kennedy L**. Limited joint mobility in insulin-dependent diabetes: relationship to retinopathy, peripheral nerve function and HLA status. *Q J Med* 1985, 56, 377-84.
- 20) Lyons TJ, **Kennedy L**. Effect of *in vitro* non-enzymatic glycosylation of human skin collagen on susceptibility to collagenase digestion. *Eur J Clin Invest* 1985, 15,128-131.
- 21) Ritchie CM, Walshe K, **Kennedy L**, Atkinson AB et al. Unusual presentations of acanthosis nigricans and insulin resistance in a brother and sister. *British Med J* 1985, 290,1320.
- 22) Hadden DR, Blair ALT, Wilson EA, Boyle DMcC, Atkinson AB, **Kennedy L**, et al. Natural history of diabetes presenting age 40-69: a prospective study of the influence of intensive dietary therapy. *Q J Med* 1986, 230, 579-98.
- 23) McCance DR, Coulter D, Smye M, **Kennedy L**. Effect of fluctuations in albumin on serum fructosamine. *Diabetic Med* 1987, 4, 434-36.

- 24) Archbold GP, Lavery TD, **Kennedy L**, et al. Effect of dietary therapy on serum HDL cholesterol and other lipids in type 2 diabetes. *Annals Clin Biochem* 1987, 24 (Suppl), 141-42.
- 25) McCance DR, Ritchie CM, **Kennedy L**. Is HbA1c superfluous in non-insulin-dependent diabetes? *Diabetes Care* 1988, 11, 512-14.
- 26) Ritchie CM, McIlrath EM, Hadden DR, Weaver JA, **Kennedy L**, Atkinson AB. Renal artery stenosis in hypertensive diabetic patients. *Diabetic Med* 1988, 5, 265-67.
- 27) McCance DR, Clark KC, Smye M, **Kennedy L**. Serum fructosamine in uraemia, myeloma, and acute inflammatory disorders - relation to serum glucose and albumin levels. *Annals Clin Biochem* 1988, 26, 63-68.
- 28) Rudenski AS, Hadden DR, Atkinson AB, **Kennedy L** et al. Natural history of pancreatic islet B-cell function in type 2 diabetes mellitus studied over six years by homeostasis model. *Diabetic Med* 1988, 5, 36-41.
- 29) Jack CM, Sheridan B, **Kennedy L**, Stout RW. Non-enzymatic glycosylation of low-density lipoprotein. Results of an affinity chromatography method. *Diabetologia* 1988, 31, 126-28.
- 30) McCance DR, Atkinson AB, Hadden DR, Archer DB, **Kennedy L**. Long-term glycaemic control and diabetic retinopathy. *Lancet* 1989, 2, 824-28.
- 31) McCance DR, Traub AI, Harley JMG, Hadden DR, **Kennedy L**. Urinary albumin excretion in diabetic pregnancy. *Diabetologia* 1989, 32, 236-39.
- 32) Atkinson AB, **Kennedy L**, Andrews WJ, Burke B, Hadden DR, Ritchie CM, Sheridan B, Traub AI, Walshe K. Diverse endocrine presentations of the syndrome of acanthosis nigricans and insulin resistance. *J Roy Coll Phys Lond* 1989, 165-169.
- 33) McCance DR, Hadden DR, Atkinson AB, Johnston H, **Kennedy L**. The relationship between long-term glycaemic control and diabetic nephropathy. *Q J Med* 1992, 297, 53-61.
- 34) McCance DR, **Kennedy L**, et al. Long-term glycaemic control and neurological function in IDDM patients. *Diabetes Care* 1993, 16, 1291-93.
- 35) McCance DR, Crowe G, **Kennedy L** et al. Incidence of microvascular complications in type 1 diabetic subjects with limited joint mobility: a ten year prospective study. *Diabetic Med* 1993, 10, 807-10.
- 36) Beatty OL, Ritchie CM, Hadden DR, **Kennedy L** et al. Is a random urinary albumin concentration a useful screening test in insulin-dependent diabetic patients? *Irish J Med Sci* 1994, 163, 406-09.

37) Ritchie CM, Beatty OL, McKnight JA, Hadden DR, **Kennedy L**, Atkinson AB. Prevalence of hypertension and albuminuria in a teaching hospital diabetes clinic. *Diabetes Res Clin Prac* 1995, 27, 69-76.

38) Beatty OL, Bell PM, Hadden DR, Atkinson AB, **Kennedy L**. Assessment of insulin secretion in NIDDM and its response to dietary therapy: importance of prevailing steady state plasma glucose. *Q J Med* 1995, 88, 257-62.

39) Beatty OL, Ritchie CM, Bell PM, Hadden DR, **Kennedy L**, Atkinson AB. Microalbuminuria as identified by a spot morning urine specimen in non-insulin dependent diabetes; an eight year follow-up study. *Diabetic Med* 1995, 12, 261-266.

40) Hadden DR, Patterson CC, Atkinson AB, **Kennedy L** et al. Macrovascular disease and hyperglycaemia: 10 year survival analysis in type 2 diabetes mellitus: the Belfast diet study. *Diabetic Med* 1997, 14, 663-672.

41) Roberts RN, Traub AI, **Kennedy AL**, Hadden DR. Glycosylated haemoglobin and hypertension arising in pregnancy. *Br J Obs Gyn*, 1998, 105, 1122-1124.

Diabetic Reviews and Comments

1) **Kennedy L**. Relation of HDL cholesterol concentration to type of diabetes and its control. *Diabetes News*, 1980, 3, 3.

2) **Kennedy L**, Merimee TJ. Evaluation of hypoglycemia. *Comprehensive Therapy* 1980, 6, 62-67.

3) **Kennedy L**, Hadden DR. Fructosamine in diabetic pregnancy. *Lancet* 1983, 3, 1193.

4) **Kennedy L**. Metabolic and hormonal effects of sulphonylurea drugs. *Proc IDF Congress, Nairobi, Kenya, Excerpta Med* 1983.

5) **Kennedy L**, Baynes JW. Non-enzymatic glycosylation and the chronic complications of diabetes: an overview. *Diabetologia* 1984, 26, 93-98.

6) Hadden DR, **Kennedy L**. Fructosamine (glycosylated protein) and the diagnosis of diabetes. *Diabetic Med* 1984, 1, 91-92.

7) **Kennedy L**. Labile glycosylated haemoglobin - is it clinically important? *Diabetic Med* 1985, 2, 198-99.

8) **Kennedy L**, Ritchie CM, Smye M, Lloyd D. Current status of assays for non-enzymatic glycosylation of serum proteins. *Proc IDF Congress, Madrid, Spain, Excerpta Med* 1985.

- 9) **Kennedy L**, Ritchie CM, Lyons TJ, Beacom R. Limited joint mobility in diabetes - some clinical and biochemical aspects. Proc IDF Congress, Madrid, Spain, Excerpta Med 1985.
- 10) **Kennedy L**, Lyons TJ. Nonenzymatic glycosylation. British Med Bull 1989, 45, 174-90.
- 11) McCance DR, **Kennedy L**. Glycated haemoglobin and fructosamine in diabetic management. Diabetes Nutr Metab 1990, 3, 173-77.
- 12) **Kennedy L**. Evidence that glucose control prevents microvascular complications of diabetes. Diabet, Excerpta Med 1992.
- 13) **Kennedy L**. Hyperglycaemia and the development of diabetic microvascular complications - no longer "whether" but "how". Proc R Coll Phys Edinburgh 1995, 25, 251-259.
- 14) **Kennedy L**, Lyons TJ. Macrovascular disease and glycooxidation in non-insulin-dependent diabetes mellitus. Metabolism 1997, 46 (Suppl 1), 14-21.

Endocrinology (non diabetic)

- 1) **Kennedy L**, Montgomery DAD. Myxoedema in pregnancy. British J Obs Gyn 1978, 85, 225-28.
- 2) **Kennedy L**, Montgomery DAD. Bromocriptine for Cushing's disease. British Med J 1977, 1, 1085.
- 3) **Kennedy L**, Sheridan B, Montgomery DAD. ACTH and cortisol responses to bromocriptine, and results of long-term treatment, in Cushing's disease. Acta Endocrin 1978, 461-67.
- 4) **Kennedy L**, Montgomery DAD, Welbourn RB. Hypothalamic-pituitary-adrenal function of untreated long-term survivors following sub-total adrenalectomy for Cushing's disease. Irish J Med Sci 1978, 147, 420-424.
- 5) McCluskey D, Lyness R, Kelly G, **Kennedy L** et al. T-lymphosarcoma cell leukaemia - a case report. Irish Med J 1979,
- 6) Todd G, Love AHG, Sheridan B, **Kennedy L**. Prolactin and coeliac disease. Lancet 1984, 1, 574.
- 7) Manolas KJ, Farmer HM, Wilson HK, **Kennedy L** et al. The pituitary before and after adrenalectomy for Cushing's syndrome. World J Surg 1984, 8, 374-87.

- 8) **Kennedy L**, Atkinson AB, Johnston H, Sheridan B, Hadden DR. Serum cortisol concentrations during low-dose dexamethasone suppression test to screen for Cushing's syndrome. *British Med J* 1984, 289, 1188-91.
- 9) Atkinson AB, **Kennedy L**, Sheridan B. Six year remission of ACTH-dependent Cushing's syndrome using bromocriptine. *Postgrad Med J* 1985, 61, 239-42.
- 10) Atkinson AB, Chestnutt A, Crothers E, Woods R, Weaver JA, **Kennedy L**, Sheridan B. Cyclical Cushing's disease: two distinct rhythms in a patient with a basophil adenoma. *J Clin Endocrin Metab* 1985, 60, 328-32.
- 11) Atkinson AB, **Kennedy L**, Carson D et al. Five cases of cyclical Cushing's syndrome. *British Med J* 1985, 291, 1453-57.
- 12) Bell PM, Hadden DR, **Kennedy L** et al. Bromocriptine lowers growth hormone in acromegaly. *Arch Int Med* 1986, 146, 1145-49.
- 13) Beacom R, Atkinson AB, **Kennedy L** et al. Studies of hypothalamic-pituitary structure and function in patients previously treated with bilateral adrenalectomy alone for Cushing's disease. *Clin Endocrin* 1986, 24, 107-16.
- 14) Barton D, McGuinness S, Hadden DR, Harley JMG, **Kennedy L** et al. Outcome of pregnancy in patients managed conservatively for hyperprolactinaemia. *Irish Med J* 1987, 80, 147-51.
- 15) **Kennedy L**, Atkinson AB, Traub AI, Sheridan B. Short term administration of gonadotropin-releasing hormone analog to a patient with testosterone -secreting ovarian tumor. *J Clin Endocrin Metab* 1987, 64, 1320-22.
- 16) McCance DR, Hadden DR, **Kennedy L** et al. Clinical experience with ketoconazole as a therapy for patients with Cushing's syndrome. *Clin Endocrin* 1987, 27, 593-99.
- 17) Ritchie CM, Hadden DR, **Kennedy L** et al. Pathogenesis of hypertension in Cushing's disease. *J Hypertension* 1987, 5 (suppl 5), S497-99.
- 18) Beringer T, McClements B, Weir I, Gilmore DH, **Kennedy L**. Hypopituitarism in the elderly in the presence of elevated TSH levels. *Postgrad Med J* 1988, 64, 943-44.
- 19) Atkinson AB, McAteer EJ, Hadden DR, **Kennedy L**, Sheridan B, Traub AI. A weight-related intravenous dexamethasone suppression test distinguishes obese controls from patients with Cushing's syndrome. *Acta Endocrin* 1989, 120, 753-59.
- 20) McCance DR, McIlrath E, McNeill A, Gordon DS, Hadden DR, **Kennedy L**, Sheridan B, Atkinson AB. Bilateral inferior petrosal sinus sampling as a routine procedure in ACTH-dependent Cushing's syndrome. *Clin Endocrinol* 1989, 30, 157-66.

- 21) Atkinson AB, Beacom R, **Kennedy L** et al. Plasma ACTH responses to cortisol infusion are similar in patients with primary hypoadrenalism and patients studied some years after bilateral adrenalectomy for Cushing's disease. *Clin Endocrin* 1989, 30, 855-67.
- 22) McKnight JA, McCance DR, Hadden DR, **Kennedy L**, Roberts G, Sheridan B, Atkinson AB.
Basal and saline-stimulated levels of plasma atrial natriuretic factor in acromegaly. *Clin Endocrinol* 1989, 31, 431-38.
- 23) Harper MA, Murnaghan GA, **Kennedy L**, Hadden DR, Atkinson AB. Pheochromocytoma in pregnancy. Five cases and a review of the literature. *Br J Obst Gyn* 1989: 96; 594-906.
- 24) Ritchie CM, Sheridan B, Fraser R, Hadden DR, **Kennedy L**, Atkinson AB. Studies on the pathogenesis of hypertension in Cushing's disease and acromegaly. *Q J Med* 1990, 76, 855-67.
- 25) Ritchie CM, Atkinson AB, **Kennedy AL**, Lyons AR, Gordon DS, Fannin T, Hadden DR. Ascertainment and natural history of treated acromegaly in Northern Ireland. *Ulster Med J* 1990, 59, 55-62.
- 26) McKnight JA, McCance DR, Sheridan B, McIlrath E, Hadden DR, **Kennedy L**, Atkinson AB. A long-term dose response study of somatostatin analogue (SMS 201-995, Octreotide) in resistant acromegaly. *Clin Endocrin* 1991, 34, 119-25.
- 27) Morrison P, Hadden DR, Hughes AE, **Kennedy L** et al. Gene probe analysis in an informative family with multiple endocrine neoplasia syndrome type 2A (MEN 2A). Improvement in carrier risk estimation. *Q J Med* 1991, 79, 597-603.
- 28) Atkinson AB, McCance DR, **Kennedy L**, Sheridan B. Cyclical Cushing's syndrome first diagnosed after pituitary surgery - a trap for the unwary. *Clin Endocrin* 1992, 36, 297-300.
- 29) Whitehead HM, Boreham C, McIlrath EM, Sheridan B, **Kennedy L**, Atkinson AB, Hadden DR. Growth hormone treatment of adults with growth hormone deficiency: results of a 13-month placebo-controlled crossover study. *Clin Endocrin* 1992, 36, 45-52.
- 30) McCance DR, Gordon DS, Fannin TF, Hadden DR, **Kennedy L**, Sheridan B, Atkinson AB. Assessment of endocrine function after transsphenoidal surgery for Cushing's disease. *Clin Endocrinol* 1993, 38, 79-86.
- 31) Beatty OL, Russell CFJ, **Kennedy L** et al. Pheochromocytoma in Northern Ireland: a 21 year review. *Eur J Surg* 1996, 162, 695-702.
- 32) Heaney A, Loughrey G, McCance D, McIlrath E, Hadden D, **Kennedy L**, Sheridan B, Atkinson AB. Is whole-lung CT scanning still necessary in all cases of ACTH-dependent Cushing's syndrome in the era of petrosal sinus sampling? *Q J Med* 1999, 92, 335-340.

33) Nizam S, **Kennedy L**. Diagnostic confusion due to thyroid binding globulin excess in a patient with TSH-secreting pituitary adenoma. Submitted for publication, 2000.

Endocrine Reviews and Comments

- 1) **Kennedy L**. Assessment and management of the prolactin secreting adenoma. Proc R Coll Phys Edinburgh 1986.
- 2) **Kennedy L**. Radioactive iodine treatment of thyrotoxicosis. Proc Eur Thyroid Assoc 1986.
- 3) McCance DR, Sheridan B, **Kennedy L**, Atkinson AB. Ketoconazole therapy in Cushing's disease. N Engl J Med 1988 (letter).

Miscellaneous

- 1) Adgey AAJ, Campbell NPC, Webb SW, **Kennedy L**, Pantridge JF. Transthoracic ventricular defibrillation in the adult. Med Instrumentation 1979, 12, 17-20.
- 2) Dinsmore W, **Kennedy L**, McCluskey D et al. Acquired immune deficiency syndrome in Northern Ireland. Ulster Med J, 1986,
- 3) **Kennedy L**. Book review: "The Maillard reaction in aging, diabetes, and nutrition." Diabetic Med 1991.

Chapters in books

- 1) **Kennedy L**. Education - an overview from a physician.
World Book of Diabetes in Practice, 1988. Krall LP, Alberti KGMM Eds. Elsevier Science Publishers.
- 2) McCance DR, **Kennedy L**. The concept and measurement of diabetic control.
Textbook of Diabetes, 1991. Pickup JC, Williams G Eds. Blackwell Scientific Publications.
- 3) **Kennedy L**. Glycated haemoglobin and other proteins.
The International Textbook of Diabetes Mellitus, 1992. Alberti KGMM, DeFronzo RA, Keen H, Zimmet P Eds. John Wiley and Sons Ltd.
- 4) **Kennedy L**. The possible role of glycation in the pathogenesis of atherosclerosis.

Heart Disease in Diabetes. 1992. Stout RW Ed. Kluwer Academic Publishers.

Invited Lectures

1985 - Inaugural **Nordisk Irish Endocrine Lecturer** of the Irish Endocrine Society.

1994 - **Honeyman-Gillespie Lecturer** - endowed annual lecture at the University of Edinburgh

In addition to the above “named” lectures I have delivered invited lectures at symposia held in conjunction with the following national and international societies:-

- Association of Clinical Biochemists (UK) - Eastbourne 1985; Glasgow 1986; Newcastle 1987; Glasgow 1995.
- International Diabetes Federation - Nairobi 1982; Madrid 1985.
- British Diabetic Association - Exeter 1989.
- Congress of USSR Diabetologists - Moscow 1989.
- Lithuanian Endocrine Society - Kaunas 1993.

Research Funding - Dr Laurence Kennedy

Between August 1978 and July 1980 I was in receipt of funding (\$7,500 per annum) from the Department of Health in Northern Ireland towards my salary as a Research Fellow in Endocrinology at the University of Florida.

Between 1980 and 1992, in collaboration with my colleagues Dr DR Hadden and Dr AB Atkinson, I successfully obtained funding from the Endowment Funds of the Royal Victoria Hospital, Belfast, and the Department of Health in Northern Ireland, to cover the salary of Research Fellows in Endocrinology, plus a small amount for consumables, travel etc (In the UK at that time many of the other costs associated with clinical research were absorbed into the budget of the National Health Service and therefore would be hard to quantify). During those 12 years we always had at least one Fellow, sometimes two, in a Research capacity.

1982-1992 Principal Investigator in the United Kingdom Prospective Diabetes Study, which received funding from the British Medical Research Council, the British Diabetic Association, the ADA, the JDF, the Wellcome Medical Foundation, and several pharmaceutical companies.

1985 - Project grant from British Diabetic Association to examine HbA1c as a screening test in pregnancy - \$8,000.

1997 - Principal Investigator in clinical trial of Insulin analog X14, NovoNordisk, at University of North Carolina, Chapel Hill, NC.

1997 - Principal Investigator in clinical trial of Voglibose (alpha-glucosidase inhibitor) - Takeda Pharmaceuticals, at University of North Carolina, Chapel Hill, North Carolina.

1998 to present - Principal Co-investigator in clinical trial of somatotropin treatment of growth hormone deficient adults, Eli Lilly & Co, at University of Florida, Gainesville, Florida.

1998 to present - Principal Investigator in clinical trial of Niaspan (extended release niacin) in Type 2 diabetes - Kos Pharmaceuticals, at University of Florida, Gainesville, Florida.

1999 to present - Principal Investigator in clinical trial of anti-glycation agent EXO-226 on renal dysfunction in diabetic patients, Exocell, Inc, (protocol EXO-04R2), at University of Florida, Gainesville, Florida.

1999 to present – Principal Investigator in clinical trial of new oral antidiabetic agent in combination with metformin in diabetic patients, Glaxo, at University of Florida, Gainesville, Florida.

2000 – Co Principal Investigator in Phase 1 clinical trial of long acting growth hormone in adults with growth hormone deficiency, Takeda America, at University of Florida, Gainesville, Florida.

2000 – Principal Investigator in Phase 2 clinical trial of a new triglyceride lowering drug in adult patients with hypertriglyceridemia, Tap Holdings Inc, at University of Florida, Gainesville, Florida.

2000 – Principal Investigator in clinical trial of a 20 week multicenter, double-blind, randomized parallel-group fixed dose study to prospectively evaluate the efficacy, safety and tolerability of oral nateglinide monotherapy (120 mg), compared to oral rosiglitazone monotherapy (8 mg) in patients with Type 2 diabetes mellitus inadequately controlled with diet and exercise alone (#0127), Novartis Pharmaceuticals Corp., at University of Florida, Gainesville, Florida

2000 – Principal Investigator in clinical trial of a 24 week multicenter, double-blind, randomized, parallel-group, fixed dose study to prospectively evaluate the safety, efficacy and tolerability of oral nateglinide plus rosiglitazone combination therapy compared to oral rosiglitazone monotherapy and diet and exercise, (#A2301), Novartis Pharmaceuticals Corp., at University of Florida, Gainesville, Florida

2000 – Principal Investigator in Investigator-Initiated clinical trial of Avandia in patients with myotonic dystrophy. Grant from SmithKline Beecham at University of Florida, Gainesville, Florida.